



MMWR

Morbidity and Mortality Weekly Report

Weekly

July 16, 2004 / Vol. 53 / No. 27

Genetic Testing for Breast and Ovarian Cancer Susceptibility: Evaluating Direct-to-Consumer Marketing — Atlanta, Denver, Raleigh-Durham, and Seattle, 2003

Breast and ovarian cancer are the second and fifth leading causes of cancer death, respectively, among women in the United States (1). One in eight women will have breast cancer during their lifetimes, and one in 70 will have ovarian cancer. Mutations in two genes, BRCA1 and BRCA2 (BRCA1/2), are associated with predisposition for inherited breast and ovarian cancer and are identified in 5%–10% of women with breast or ovarian cancer (BOC) (2). Since 1996, genetic testing for these mutations has been available clinically (3); however, population-based screening is not recommended because of the complexity of test interpretation and limited data on clinical validity and utility (1,4–6). Despite the test's limited applicability in the general population, the U.S. provider of clinical BRCA1/2 testing (Myriad Genetic Laboratories, Inc., Salt Lake City, Utah) conducted a pilot direct-to-consumer (DTC) marketing campaign in two cities (Atlanta, Georgia, and Denver, Colorado) during September 2002–February 2003. Although DTC advertisements have been used to raise consumer awareness about pharmaceuticals (7), this was the first time an established genetic test was marketed to the public. To assess the impact of the campaign on consumer behaviors and health-care provider practices, CDC and the respective state health departments for the pilot cities and two comparison cities (Raleigh-Durham, North Carolina, and Seattle, Washington) surveyed consumers and providers. This report summarizes results of those surveys, which indicated that consumer and provider awareness of BRCA1/2 testing increased in the pilot cities and that providers in these cities perceived an impact on their practice (e.g., more questions asked about testing, more BRCA1/2 tests requested, and more tests ordered). However, in all four cities, providers often lacked knowledge to advise patients about inherited BOC and testing. These findings underscore the need for evidence-based

recommendations on appropriate use of genetic tests and education of providers and the public to achieve maximum individual and public health benefit from genetic testing.

Women aged 25–54 years with personal or family histories of BOC and their health-care providers were target audiences of the DTC campaign. The campaign consisted of television, radio, and print advertising to raise awareness about BRCA1/2 testing and to motivate women to ask their providers how genetic testing might help assess BOC risk and guide them to effective medical management options. Providers received precampaign information and patient support materials (8).

During April 21–May 20, 2003, a 51-question consumer telephone survey was conducted by using randomly generated household telephone numbers. Approximately 1,600 women were targeted for participation. Survey questions addressed family history, campaign awareness, interest in BRCA1/2 testing, cancer concerns, and interactions with health-care providers, family members, and friends. On May 1, 2003, providers were mailed a 35-question survey and a monetary incentive. Questions surveyed knowledge of inherited BRCA1/2 mutations, campaign awareness, and perceived changes in practice subsequent to the campaign. Approximately 1,600 physicians were selected randomly from the

INSIDE

- 606 Trichinellosis Associated with Bear Meat — New York and Tennessee, 2003
- 610 Prevalence of Anemia Among Displaced and Nondisplaced Mothers and Children — Azerbaijan, 2001
- 615 West Nile Virus Activity — United States, July 7–13, 2004
- 615 Update: Investigation of Rabies Infections in Organ Donor and Transplant Recipients — Alabama, Arkansas, Oklahoma, and Texas, 2004

The *MMWR* series of publications is published by the Epidemiology Program Office, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

SUGGESTED CITATION

Centers for Disease Control and Prevention. [Article Title]. *MMWR* 2004;53:[inclusive page numbers].

Centers for Disease Control and Prevention

Julie L. Gerberding, M.D., M.P.H.

Director

Dixie E. Snider, M.D., M.P.H.

(Acting) Deputy Director for Public Health Science

Tanja Popovic, M.D., Ph.D.

(Acting) Associate Director for Science

Epidemiology Program Office

Stephen B. Thacker, M.D., M.Sc.

Director

Office of Scientific and Health Communications

John W. Ward, M.D.

Director

Editor, MMWR Series

Suzanne M. Hewitt, M.P.A.

Managing Editor, MMWR Series

Douglas W. Weatherwax

(Acting) Lead Technical Writer/Editor

Jude C. Rutledge

Teresa F. Rutledge

Writers/Editors

Lynda G. Cupell

Malbea A. LaPete

Visual Information Specialists

Kim L. Bright, M.B.A.

Quang M. Doan, M.B.A.

Erica R. Shaver

Information Technology Specialists

Division of Public Health Surveillance and Informatics

Notifiable Disease Morbidity and 122 Cities Mortality Data

Robert F. Fagan

Deborah A. Adams

Felicia J. Connor

Lateka Dammond

Rosaline Dhara

Donna Edwards

Patsy A. Hall

Pearl C. Sharp

American Medical Association master list to be proportionally representative of four specialties (i.e., family practice, internal medicine, obstetrics/gynecology, and oncology).

Consumer Survey

A total of 1,635 women completed the survey (participation rate: 45%); the majority (79%) were non-Hispanic white, with a median age of 40 years and more than a high school education (75%). Thirteen percent had a family history of BOC in a first-degree relative (e.g., parent or sibling). In the pilot cities, consumers were substantially more likely than those in the comparison cities to have heard of the test and to have seen a television, radio, or magazine advertisement; however, perceived knowledge about testing did not differ between consumers in the pilot and comparison cities (Table 1). No differences were observed between pilot and comparison cities in the percentage of women who reported talking to anyone about the test (Table 1) or in the level of concern about their risk for BOC. Among women who had heard of the test, interest in testing did not vary by city (Table 1). Among women who had heard of and were interested in the test, 20% had a first-degree relative with BOC, compared with 17% of women who had heard of the test but were not interested.

Provider Survey

A total of 1,054 providers completed the survey (participation rate: 66%); the majority (66%) were male, had been in practice for >10 years (62%), and evaluated <100 patients per week (65%). In the pilot cities, providers were more likely than those in comparison cities to report that they and their patients saw or heard an advertisement about genetic testing for BOC (Table 2). When asked to compare the previous 6 months with the same period 1 year before, more providers in the pilot cities than in comparison cities reported an increase in the number of patients who had asked questions about testing, asked for genetic counseling referrals to consider testing, and requested testing. Providers in the pilot cities also reported ordering more tests but not more referrals to genetics or oncology centers (Table 2).

Provider knowledge did not differ between the pilot and comparison cities. Fifty-two percent of providers were aware that a BRCA1/2 mutation can be inherited from either parent, and 46% knew that a woman with a sister with a known BRCA1 mutation has a 50% risk for inheriting the same mutation. Oncologists and obstetricians/gynecologists were more likely to answer knowledge questions correctly. The majority of providers believed that learning more about genetic testing for BOC risk was relevant to their practice.

TABLE 1. Number and percentage of consumers who reported being aware of BRCA1/2 testing and were interested in having genetic testing for hereditary breast and ovarian cancer, by city and survey question — four cities, 2003*

Question	Pilot cities		Comparison cities		p value†
	Denver, Colorado (N = 401)	Atlanta, Georgia (N = 410)	Seattle, Washington (N = 421)	Raleigh-Durham, North Carolina (N = 403)	
	No. (%)	No. (%)	No. (%)	No. (%)	
Ever heard of a genetic test for breast/ovarian cancer risk called B-R-C-A or BRACAnalysis®?	178 (45)	159 (39)	98 (24)	81 (21)	S§
If "yes," are you interested in having the BRACAnalysis® test?	63 (38)	66 (46)	33 (36)	23 (31)	NS¶
Saw/heard an advertisement about a genetic test to determine a woman's risk for breast or ovarian cancer in the past 6 months?	144 (36)	172 (42)	50 (12)	91 (23)	S
How would you describe your overall knowledge about genetic testing for breast and ovarian cancer?					
Little/Nothing	274 (68)	285 (70)	289 (69)	294 (73)	NS
Some	117 (29)	114 (28)	114 (27)	99 (25)	
A lot	9 (2)	10 (2)	16 (4)	8 (2)	
Ever talked to anyone about the test?*	31 (8)	23 (6)	28 (7)	23 (6)	NS
Spoke with health-care provider	18 (4)	19 (5)	23 (5)	16 (4)	
Spoke with friends/family members	19 (5)	14 (3)	17 (4)	10 (2)	

* Sum of percentages might not always total 100 because of "don't know" responses. Missing values are excluded.

† Values of $p < 0.05$ are considered significant. Calculations are between pilot cities combined and comparison cities combined.

§ Significant.

¶ Not significant.

** Responses not mutually exclusive.

TABLE 2. Number and percentage of health-care providers who reported being aware of BRCA1/2 test advertisements and reported practices regarding genetic testing for hereditary breast and ovarian cancer, by city and survey question — four cities, 2003*

Question	Pilot cities		Comparison cities		p value†
	Denver, Colorado (N = 270)	Atlanta, Georgia (N = 292)	Seattle, Washington (N = 328)	Raleigh-Durham, North Carolina (N = 164)	
	No. (%)	No. (%)	No. (%)	No. (%)	
Personally saw/heard an advertisement about genetic testing for breast/ovarian cancer risk in the past 6 months?	103 (39)	126 (44)	59 (18)	47 (29)	S§
Patients mentioned they had seen/heard an advertisement for breast/ovarian cancer risk in the past 6 months?	74 (28)	78 (27)	26 (8)	16 (10)	S
Comparing the last 6 months to the same period last year, have					
Questions about testing increased?	96 (41)	96 (39)	63 (23)	30 (22)	S
Requests for referrals increased?	57 (25)	42 (18)	36 (13)	14 (11)	S
Actual referrals to genetics or oncology increased?	75 (33)	66 (27)	77 (28)	31 (24)	NS¶
Requests for tests increased?	72 (31)	59 (25)	40 (14)	18 (14)	S
Number of tests ordered increased?	35 (17)	41 (18)	22 (9)	10 (9)	S

*Sum of percentages might not always total 100 because of rounding.

† Values of $p < 0.05$ are considered significant. Calculations are between pilot cities combined and comparison cities combined.

§ Significant.

¶ Not significant.

Reported by: J Jacobellis, PhD, Colorado Dept of Public Health and Environment. L Martin, MS, Georgia Dept of Human Resources. J Engel, MD, North Carolina Div of Public Health. J VanEenwyk, PhD, Washington State Dept of Health. LA Bradley, PhD, Office of Genomics and Disease Prevention, Office of the Director; S Kassim, MD, C Jorgensen, DrPH, Div of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion; JA Litch, MD, MF Myers, PhD, EIS officers, CDC.

Editorial Note: The findings from the provider survey indicate that DTC advertisements might have motivated women interested in learning more about BRCA1/2 testing to talk to

their physicians and request testing. Findings from the consumer survey suggest that women in the pilot cities were more aware of BRCA1/2 testing than those in the comparison cities. No evidence suggested an increased interest in the test among women most suited for BRCA1/2 testing (i.e., those having a first-degree relative with BOC). The demonstrated lack of provider knowledge underscores the need for additional education; providers in certain specialties were unprepared to address the complexities surrounding genetic testing for susceptibility to BOC.

Complexities of the BRCA1/2 test have been described (2,4,5). Most BOC is not associated with BRCA1/2 mutations. Testing has been directed at women with a family history of cancer; however, even in this group, test interpretation is complex, and genetic counseling is recommended (4-6). Women with an identified BRCA1/2 mutation have a substantially increased lifetime risk for BOC, but morbidity and mortality might be reduced through increased surveillance, chemoprevention, or prophylactic surgery (2). To assess knowledge of genetic testing for susceptibility to BOC, CDC has funded a review of BRCA1/2 testing in women with a family history of BOC (9) and an assessment of the clinical utility of BRCA1/2 counseling and testing by the U.S. Preventive Services Task Force (10).

The findings in this report are subject to at least five limitations. First, information was not available for nonresponders. Whether responders differed from nonresponders with respect to demographics and other variables such as cancer family history is unknown. Second, because of the low consumer response rate (45%), a potential for bias might have been introduced; responders might have a different level of knowledge or interest in participating in testing or the survey. Third, the lag time between the campaign and the survey might not have been sufficient to allow those interested to pursue and complete testing. Fourth, quantifying the numbers of tests performed and appropriateness of testing was not possible because the information is proprietary and not available. Finally, objective data on the appropriateness of education, counseling, and tests ordered by providers are not available.

In the United States, regulatory oversight of genetic testing is limited, and no process exists for review of the accuracy and impact of advertising claims about validity and utility of genetic tests. However, translation of genomic discoveries to medical practice continues to yield new applications for diagnosis, promise for new disease treatments and preventions, and increased consumer interest and demand for genetic testing. Public health agencies should provide information about genetic tests to educate consumers and providers and protect consumers by ensuring the safe and effective use of genetic tests. Collaboration among public health agencies, health-care providers, the clinical laboratory/biotechnology industry, and professional organizations will be required to develop a systematic approach for evidence-based assessment of the clinical validity and utility of genetic tests, identify gaps in knowledge, and to determine test efficacy, utilization, and access through postmarket surveillance. Such partnerships will be needed to support public health responses as genomics becomes more integrated into health promotion and disease prevention.

Acknowledgments

This report is based on contributions by J Mouchawar, MD, Kaiser Permanente, Denver, Colorado. B Bernhardt, MS, Johns Hopkins Medical Institutions, Baltimore, Maryland. D Irwin, PhD, Univ of North Carolina Center for Genomics, Chapel Hill, North Carolina. DJ Bowen, PhD, Fred Hutchinson Cancer Research Center; BB McGrath, PhD, Univ of Washington School of Nursing, Seattle; DL Doyle, MS, Genetics Svcs Section, Washington State Dept of Health. L Armstrong, PhD, Div of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion; K Peterson, MS, Office of Genomics and Disease Prevention, Office of the Director; A Faucett, MS, K Reed, MPH, Public Health Practice Program Office, CDC.

References

1. American Cancer Society. Cancer facts and figures, 2003. Available at <http://www.cancer.org/downloads/stt/caff2003pwsecured.pdf>.
2. National Cancer Institute, National Institutes of Health. Genetics of breast and ovarian cancer (PDQ). Available at <http://www.cancer.gov/cancerinfo/pdq/genetics/breast-and-ovarian>.
3. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *J Clin Oncol* 2002;20:1480-90.
4. American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. *J Clin Oncol* 2003;21:2397-406.
5. American College of Medical Genetics Foundation. Genetic susceptibility to breast and ovarian cancer: assessment, counseling, and testing guidelines, 1999. Available at <http://www.health.state.ny.us/nysdoh/cancer/obcancer/contents.htm>.
6. American College of Obstetricians and Gynecologists. Breast-ovarian cancer screening. Washington, DC: American College of Obstetricians and Gynecologists, 2000; ACOG Committee Opinion 239.
7. U.S. General Accounting Office. Prescription drugs: FDA oversight of direct-to-consumer advertising has limitations. Washington, DC: U.S. General Accounting Office, October 2002; report no. GAO-03-177.
8. Myriad Genetic Laboratories, Inc. Consumer awareness campaign for BRACAnalysis® in Atlanta and Denver, 2002. Salt Lake City, Utah: Myriad Genetic Laboratories, Inc., 2002.
9. Haddow JE, Palomaki GE. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury MJ, Little J, Burke W, eds. *Human Genome Epidemiology*, 1st ed. New York, New York: Oxford University Press, 2004:217-33. Available at <http://www.cdc.gov/genomics/activities/fbr.htm>.
10. U.S. Preventive Services Task Force. Genetic risk assessment and testing for breast and ovarian cancer susceptibility. Available at <http://www.ahrq.gov/clinic/uspstf/uspstfqa.htm>.

Trichinellosis Associated with Bear Meat — New York and Tennessee, 2003

Trichinellosis is a parasitic infection caused by tissue-dwelling *Trichinella* roundworms and is associated traditionally with ingestion of pork from infected domestic swine. As a result of improvements in swine production, trichinellosis has

trust•wor•thy: *adj*


('trəst-"wər-thē) 1 : worthy of belief

2 : capable of being depended upon;

see also *MMWR*.



know what matters.



declined steadily in the United States (1). However, infection also can result from eating the meat of wild animals. During 1997–2001, a total of 72 cases of trichinellosis (median: 12 cases annually; range: 11–23 cases) were reported to CDC; the majority of these infections were associated with eating wild game, predominantly bear. This report describes three cases of trichinellosis associated with eating undercooked bear meat reported from New York and Tennessee in 2003. To prevent trichinellosis, persons should cook meat, particularly wild game, to an internal temperature of 160° F (71° C) (1).

Case Reports

New York. In December 2003, the New York State Department of Health was notified of a trichinellosis case in a man aged 54 years who resided in Franklin County. The patient had been hospitalized in a tertiary care center in early November with a 3-week history of diaphoresis, fever, weakness, tachycardia, diarrhea, an 8-pound weight loss, and dry cough. Laboratory testing indicated an elevated white blood cell (WBC) count (20,600/mm³ [normal: 5,000–10,000/mm³] with 33% eosinophils), hyponatremia (123 mmol sodium/L [normal: 136–145 mmol sodium/L]), elevated lactate dehydrogenase (LDH) (823 U/L [normal: 313–618 U/L]), and elevated creatinine phosphokinase (CPK) (1,554 U/L [normal: 10–250 U/L]).

The patient reported eating approximately 2 pounds of nearly raw bear meat during several meals 2 weeks before onset of symptoms. The meat had come from a custom slaughter house in upstate New York and had been frozen at -4° F (-20° C) for approximately 1 week before ingestion. Because of suspicion of trichinellosis infection, albendazole and corticosteroids were administered. Weakness and fatigue persisted through late December 2003. The patient recovered fully by February 2004.

Serum specimens collected on the third hospital day for antibody testing of *Trichinella* and other helminths were reported negative by a commercial reference laboratory. A serum specimen collected on the 11th hospital day and sent to CDC for *Trichinella* antibody testing was positive by enzyme-linked immunoassay.

The New York State Department of Environmental Conservation (NYSDEC)'s Wildlife Pathology Unit recovered nine packages of bear meat from multiple bears from the patient's freezer and identified *Trichinella* spp. larvae in five of the seven packages examined. Muscle digestion with artificial gastric juice yielded 0.5–48.0 larvae per gram of bear meat. The remaining two packages of meat were examined by the U.S. Department of Agriculture (USDA), which identified *Trichinella nativa* by polymerase chain reaction (PCR).

Tennessee. In November 2003, the Tennessee Department of Health received a report of two cases of trichinellosis in persons residing in Claiborne County. In early October, a man aged 38 years and a woman aged 54 years were admitted to a hospital with 7-day and 14-day histories of fever, respectively, chills, headache, myalgias, arthralgias, and facial swelling. The man's WBC count was 14,600/mm³, with 24% eosinophils, 13% lymphocytes, and 2% monocytes. The woman's WBC count was 16,200/mm³, with 28% eosinophils, 13% lymphocytes, and 3% monocytes. Serum obtained from both patients tested positive for *Trichinella* antibodies, and both were started on a course of albendazole and corticosteroids. Both patients have recovered fully.

Questioning of the patients revealed that, in late August 2003, the man had shot a black bear (*Ursus americanus*) in Canada. The bear was field dressed, and selected meat was packed on ice for transport to Tennessee. On August 31, the man and woman prepared and cooked the bear meat on an outdoor grill for themselves and four other persons. The man and woman ate their steaks medium rare; the four others ate their steaks well done. The remaining meat was packaged for storage in a household freezer, and the family continued to consume the meat during September.

In December, samples of the bear meat were examined histologically at the University of Tennessee College of Veterinary Medicine. Numerous *Trichinella* larvae were observed encysted in characteristic hyalinized capsules in the striated muscle tissue (Figure). The larvae had diameters of approximately 30–35 μ m, and the diagnostic morphology of the stichosome was apparent at high (400x) magnification.

FIGURE. *Trichinella* larva encysted in a characteristic hyalinized capsule in striated muscle tissue



Photo/Wadsworth Center, New York State Department of Health

Further testing of the bear meat at USDA recovered live larvae (estimated infection intensity: 350–400 larvae per gram of muscle), and PCR results were consistent with the genotype *T. nativa*.

Reported by: P Smith, MD, M Eidson, DVM, A Willsey, DVM, B Wallace, MD, M Kacica, MD, G Johnson, M Frary-Pelletieri, MS, A Burns, MS, New York State Dept of Health; W Stone, ScD, New York State Dept of Environmental Conservation. J Narro, MD, Univ of Tennessee Medical Center; C Faulkner, PhD, D Rotstein, DVM, Univ of Tennessee College of Veterinary Medicine, Knoxville; L Sheeler, PhD, P Erwin, MD, Tennessee Dept of Health. B Kirkpatrick, MD, Univ of Vermont College of Medicine, Burlington, Vermont. D Zarlega, PhD, U.S. Dept of Agriculture. P Schantz, VMD, Div of Parasitic Diseases, National Center for Infectious Diseases; F Coronado, MD, EIS Officer, CDC.

Editorial Note: Undercooked wild game has emerged in recent years as a predominant source for infection with *Trichinella* (2,3) (Box). During 1997–2001, of the 52 (72%) U.S. cases in which a source of infection was known or suspected, pork products were associated with 21 (40%) cases, and wild game was associated with 31 (60%), including 29 cases linked to bear meat (1). In Canada, the majority of trichinellosis outbreaks during the previous three decades were attributed to eating meat from wild animals (3).

Increasing local bear populations combined with the popularity of bear hunting in the northeastern United States and Canada might contribute to increased cases of *Trichinella* infection. In 2003, in New York state, a record number of approximately 1,850 bears were reported killed by hunters (4). NYSDEC provides information about trichinellosis and proper cooking instructions for wild game with each bear-hunting license issued. However, the meat from hunted animals often is given away and eaten by persons who are unaware of the need to cook the meat thoroughly enough to kill larvae. Multiple exposures also can occur when bear meat is served at wild game parties. Whereas freezing at specified temperatures kills *T. spiralis* larvae in pork, *T. nativa* is a freeze-resistant species that remains viable after freezing, even for months or years. The three cases described in this report were the result of eating improperly cooked bear meat infected with *T. nativa*.

Educational messages concerning the risks of eating meat cooked improperly do not always reach persons at risk for trichinellosis (2). To prevent future cases of trichinellosis, health-education messages should target wild game hunters who are most at risk for *Trichinella* infection (3). Information on the parasite and proper cooking should be made available at points of wild game distribution, such as custom butchers and game meat processors. To prevent trichinellosis, consumers should be advised to monitor for an adequate cooking

BOX. Epidemiology, diagnosis, treatment, and prevention of trichinellosis

Epidemiology

- Zoonotic disease caused by nematode worms of genus *Trichinella*.
- Animal reservoirs of infection include pigs, bears, seals, and numerous other omnivorous wild animals.
- Humans become infected through ingestion of meat containing infective larvae.
- Historically, pork was the most common meat source; however, in recent years, the majority of cases are related to ingestion of bear or other wild animal meat.

Clinical findings

- Disease is characterized by sudden appearance of diarrhea, fever, and muscle pain.
- Blood eosinophilia is a typical laboratory finding.
- Cardiac and neurologic sequelae occur in the most severe infections.
- Gastrointestinal symptoms can appear within a few days after ingestion of infected meat. Systemic symptoms usually appear approximately 8–15 days after ingestion.

Diagnosis and laboratory testing

- A working diagnosis is based on clinical findings (e.g., fever, muscle aches, and eosinophilia) and a history of eating raw or rare meat.
- Muscle biopsy indicating *Trichinella* larvae or serum antibody testing is essential for diagnosis.
- Antibody assays to confirm diagnosis are available through state health or commercial diagnostic laboratories.

Treatment

- Benzimidazoles (e.g., albendazole or mebendazole) are treatments of choice for symptomatic patients; efficacy dependent on early initiation of treatment.
- Corticosteroids alleviate symptoms of the inflammatory reaction.

Prevention and reporting

- Trichinellosis is a nationally notifiable disease; cases should be reported to state health departments.
- Prevention should focus on adequate cooking of meat.
- Additional information is available at <http://www.cdc.gov/ncidod/dpd/parasites/trichinosis/default.htm>.

temperature of 160° F (71° C) (1) and observe the color and texture of the meat during cooking. A change in color from red to dark gray throughout and a change in texture such that muscle fibers are easily separated from each other are indicators that meat has been rendered safe to eat (3,5). However, game meats such as bear are very dark, making interpretation of color changes difficult; for these, adequate cooking might be better judged by texture and temperature. USDA recommends a higher temperature to allow for different cooking methods (e.g., microwave cooking) that might result in uneven temperature distributions throughout the meat (6).

Symptoms associated with classic trichinellosis from *T. spiralis* include fever, facial edema, myalgias, muscle swelling, and weakness. However, as demonstrated in the *T. nativa* cases described in this report, some of these symptoms might be absent. Eosinophilia typically is present in cases of trichinellosis, and elevated blood levels of muscle enzymes (e.g., LDH and CPK) also are common. Physicians should consider trichinellosis in any ill person with eosinophilia and a history of eating wild game. Suspected cases should be reported to state health departments.

References

1. CDC. Trichinellosis surveillance—United States, 1997–2001. In: CDC Surveillance Summaries (July 25). MMWR 2003;52(No. SS-6):1–8.
2. Dworkin M, Gamble H, Zarlega D, Tennican P. Outbreak of trichinellosis associated with eating cougar jerky. J Infect Dis 1996;174:663–6.
3. Schellenberg R, Tan B, Irvine J, et al. An outbreak of trichinellosis due to consumption of bear meat infected with *Trichinella nativa* in two northern Saskatchewan communities. J Infect Dis 2003;188:835–43.
4. New York State Department of Environmental Conservation. Historic black bear harvest data. Available at <http://www.dec.state.ny.us/website/dfwmr/wildlife/wildgame/beartake.htm>.
5. Gamble HR, Bessonov AS, Cuperlovic K, et al. International Commission on Trichinellosis: recommendations on methods for the control of *Trichinella* in domestic and wild animals intended for human consumption. Vet Parasitol 2000;93:393–408.
6. Gamble HR. Parasites associated with pork and pork products. Rev Sci Tech 1997;16:496–506.

Prevalence of Anemia Among Displaced and Nondisplaced Mothers and Children — Azerbaijan, 2001

In the early 1990s, the war between Armenia and Azerbaijan over the Azeri region of Nagorno-Karabakh resulted in approximately 600,000 internally displaced persons* and

200,000 refugees† in Azerbaijan (1). After years of displacement and despite sustained humanitarian assistance, these internally displaced persons and refugees (IDP/Rs) are still coping with unfavorable living conditions and limited employment opportunities (2). Results of a 1996 CDC survey in Azerbaijan revealed high rates of malnutrition and anemia among both the IDP/R and resident populations (3) and prompted further study of the nutritional status of these populations. This report summarizes results of a 2001 survey of IDP/R and non-IDP/R mothers and children with anemia in Azerbaijan. Findings indicated that more than one third of mothers and children were anemic, with no significant difference in the overall prevalence between IDP/R and non-IDP/R populations; however, among the IDP/R population, anemia was associated with various socioeconomic factors such as education, socioeconomic status (SES)§, and area of residence. Future studies should focus on identifying causes for the high rates of anemia in Azerbaijan and developing effective interventions such as iron supplementation and behavior modification.

Data for this report are from the Azerbaijan Reproductive Health Survey, 2001 (AZRHS01), the first nationally representative reproductive health survey in Azerbaijan, which was conducted with technical assistance from CDC at the invitation of the U.S. Agency for International Development (USAID) (4). AZRHS01 was a face-to-face household survey of a probability sample of 8,246 women aged 15–44 years; a total of 7,668 (93.0%) women responded. To examine differences between IDP/R and non-IDP/R women and children, the survey oversampled those regions heavily populated by IDP/Rs.

The survey also included a nutritional assessment module consisting of anthropometric (i.e., height and weight) and hemoglobin (Hb) measurements. This module was administered only to mothers with at least one child aged 3–59 months and to those mothers' children aged 12–59 months. A total of 2,206 mothers and 2,274 children were eligible to participate in this anemia substudy. Before fingerstick blood samples were taken, mothers were asked to provide written consent for collection of blood from themselves and their children. Trained personnel measured Hb levels on the HemoCue® (HemoCue, Inc., Lake Forest, California) hemoglobin test system.

* Persons who have fled their homes because of armed conflict or fear of persecution for reasons of race, religion, nationality, social group membership, or political opinion.

§ Initially represented by a score based on household amenities and goods (e.g., telephone, indoor toilet, central heat, television, refrigerator, video recorder, automobile, cellular phone, uncrowded living conditions, and recreational home/villa). Scores ranged from zero (i.e., no amenities and goods) to 10 (i.e., all amenities and goods). Respondents with scores of ≤3 were classified as having low SES, and those with scores of ≥4 as having middle-high SES.

* Persons who have fled their homes because of armed conflict or fear of persecution for reasons of race, religion, nationality, social group membership, or political opinion, and who have not crossed an internationally recognized national border.

Mothers were informed immediately of their results and those of their children. Blood samples were collected from 1,913 (90.2%) mothers and 2,047 (89.7%) children. After respondents with missing Hb results or outlying levels (i.e., <6 g/dL or >17 g/dL) were excluded, the final sample consisted of 1,906 mothers (356 IDP/Rs and 1,550 non-IDP/Rs) and 2,017 children (373 IDP/Rs and 1,644 non-IDP/Rs).

Anemia was defined according to the 1998 CDC criteria (5) as an Hb level of <12.0 g/dL for nonpregnant mothers, adjusting for weeks of gestation for pregnant mothers[†]. Among children, levels for anemia were age-specific (<11.0 g/dL for children aged 12–23 months and <11.1 g/dL for children aged 24–59 months). Survey results were weighted to adjust for the sampling design. Because $<2\%$ of the survey participants were refugees, data for refugees and IDPs were combined as one group (IDP/Rs). Data were analyzed by using SAS and SUDAAN. Two-sided t-tests were used to determine the difference in anemia prevalence between IDP/Rs and non-IDP/Rs and among subgroups within those populations. Associations between sociodemographic variables and anemia prevalence were determined by using chi-square tests, which were calculated separately for the IDP/R and the non-IDP/R groups. All differences are statistically significant ($p<0.05$) unless otherwise noted.

The IDP/R and non-IDP/R mothers and children had similar sociodemographic characteristics, with the exception of housing arrangements (Table 1). At the time of the survey, approximately half (48.5%) of the IDP/R mothers were living in temporary housing (e.g., public buildings, shelters, railroad wagons, and tents); 2% of non-IDP/R mothers were living in temporary housing. Among the IDP/R mothers, 44.2% had reported receiving humanitarian assistance (e.g., food supplies, household goods, clothing, and shelter) during the previous year.

Both IDP/R and non-IDP/R mothers had a high prevalence of anemia (39.0% and 40.1%, respectively) (Table 2). Anemia prevalence also was high among children, in both the IDP/R and non-IDP/R groups (35.5% and 33.2%, respectively). The prevalence of anemia did not differ significantly by IDP/R status among mothers or among children.

Anemia prevalence was significantly higher among IDP/R mothers with less than secondary education (64.2%), compared with non-IDP/R mothers (37.5%) with a similar level of education. Among IDP/R mothers, anemia decreased with higher education (64.2% for less than secondary, 37.5% for

completed secondary, and 27.3% for technicum** or university education). Among IDP/R mothers, anemia prevalence also was associated with other socioeconomic factors, including living in rural versus urban areas (48.9% versus 31.9%); low versus medium-high SES (48.3% versus 27.4%); and receiving humanitarian aid (48.2% versus 31.2%).

For both IDP/R and non-IDP/R children, the prevalence of anemia decreased with age and was significantly higher for those whose mothers also were anemic (Table 2). Within the IDP/R group, children living in households with low SES had higher levels of anemia than those living in medium-high socioeconomic households (41.0% versus 27.6%). Children who were stunted^{††} were more likely to be anemic than children who were not stunted (48.8% versus 32.8%).

Reported by: S Rahimova, PhD, Adventist Development and Relief Agency, Azerbaijan. GS Perry, DrPH, Div of Nutrition and Physical Activity; F Serbanescu, MD, PW Stupp, PhD, TM Durant, PhD, C Crouse, MSc, Div of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion; LI Bhatti, MBBS, EIS Officer, CDC.

Editorial Note: The findings in this report indicate a high prevalence of anemia among both mothers and children in Azerbaijan, with no overall differences in prevalence between IDP/R and non-IDP/R populations. Similar high levels of anemia have been reported among women in neighboring central Asian countries (6).

Iron deficiency is the leading cause of anemia in most developing countries and disproportionately affects groups with the highest iron demands (7,8). The pattern of higher levels of anemia among younger children and women of reproductive age in Azerbaijan, along with no evidence of high prevalence of hookworms, malaria, or other micronutrient deficiencies (e.g., vitamin A) suggests that iron deficiency is the most probable cause. However, additional assessments and research are necessary to determine the causes of the high rates of anemia in Azerbaijan more conclusively.

At least two factors might have contributed to the similarity in anemia prevalence between IDP/Rs and non-IDP/Rs. IDPs outnumbered refugees by approximately 10 to 1; unlike refugees, IDPs are part of the host population, sharing the same background characteristics, food preferences, lifestyles, and risk factors for anemia as the established population. In addition, nutritional deficiencies among the IDP/R population at the beginning of displacement might have attenuated because of the humanitarian aid provided for several years by USAID and other international agencies.

[†] For women 1–12 weeks pregnant, an Hb level of <11.0 g/dL was used. For women 13–40 weeks pregnant, Hb levels were 10.6, 10.5, 10.5, 10.7, 11.0, 11.4, and 11.9 g/dL for 16, 20, 24, 28, 32, 36, and 40 weeks, respectively.

** Technical vocational school.

^{††} Children with height-for-age Z-scores <2 standard deviations below the CDC/World Health Organization reference.

TABLE 1. Selected characteristics of mothers with children aged 3–59 months and of children aged 12–59 months, by internally displaced person/refugee (IDP/R) status — Azerbaijan, 2001

Characteristic	Mothers		Characteristic	Children	
	IDP/R (n = 356) %	Non-IDP/R (n = 1,550) %		IDP/R (n = 373) %	Non-IDP/R (n = 1,644) %
Age group (yrs)			Age group (mos)		
15–24	22.0	30.1	12–23	21.2	24.1
25–34	60.2	54.8	24–35	22.9	25.7
35–44	17.8	15.2	36–47	30.8	24.1
			48–59	25.1	26.2
Residence			Residence		
Urban	58.0	50.1	Urban	58.1	48.3
Rural	42.0	49.9	Rural	41.9	51.7
Socioeconomic status (SES)*			SES		
Low	55.6	51.9	Low	59.2	54.7
Medium-high	44.4	48.1	Medium-high	40.8	45.4
Family's housing arrangements			Family's housing arrangements		
Owned/Rented property	41.3	82.1	Owned/Rented property	42.2	82.6
Living with family or friends (no rent)	10.3	15.8	Living with family or friends (no rent)	8.8	15.4
Temporary housing†	48.5	2.1	Temporary housing†	49.0	2.0
Education of mother			Sex		
Primary/Incomplete secondary	17.1	21.0	Male	58.1	51.9
Complete secondary	53.1	52.5	Female	41.9	48.1
Technicum/University	29.8	26.5			
Education of husband			Birth order		
Primary/Incomplete secondary	4.9	5.0	First	29.5	33.9
Complete secondary	39.3	41.4	Second	33.5	33.7
Technicum/University	55.8	53.6	Third or higher	37.0	32.4
Employed			Birthweight		
Yes	17.7	17.9	<2,500 g	13.0	10.8
No	82.4	82.1	≥2,500 g	80.5	82.9
			Don't know	6.5	6.3
Husband employed			Birth interval		
Yes	48.0	51.8	First birth	29.5	34.1
No	52.0	48.2	<2 years	25.4	26.6
			≥2 years	45.1	39.3
Parity			Stunted§		
1	19.3	23.8	Yes	17.0	14.3
2	32.9	37.5	No	83.0	85.7
3	30.5	24.2			
≥4	17.3	14.5	Wasting¶		
Currently pregnant			Yes	2.5	2.0
Yes	9.7	7.5	No	97.5	98.0
No	90.3	92.5			
Family received humanitarian aid during previous year			Family received humanitarian aid during previous year		
Yes	44.2	N/A**	Yes	46.8	N/A
No	55.8	N/A	No	53.2	N/A

* Initially represented by a score based on household amenities and goods (e.g., telephone, indoor toilet, central heat, television, refrigerator, video recorder, automobile, cellular phone, uncrowded living conditions, and recreational home/villa). Scores ranged from zero (i.e., no amenities and goods) to 10 (i.e., all amenities and goods). Respondents with scores of ≤3 were classified as having low SES, and those with scores of ≥4 as having medium-high SES.

† Includes public buildings (e.g., schools, farms, and factories), nongovernmental shelters, railroad wagons, mud houses, dugouts, and tents.

§ Defined as having a height-for-age Z-score <2 standard deviations below the CDC/World Health Organization (WHO) reference.

¶ Defined as having a weight-for-height Z-score <2 standard deviations below the CDC/WHO reference.

** Not applicable.

TABLE 2. Prevalence of anemia* among mothers with children aged 3–59 months and among children aged 12–59 months, by selected characteristics and internally displaced person/refugee (IDP/R) status — Azerbaijan, 2001

Characteristic	Mothers		Characteristic	Children	
	IDP/R (n = 356)	Non-IDP/R (n = 1,550)		IDP/R (n = 373)	Non-IDP/R (n = 1,644)
	% (95% CI) [†]	% (95% CI)		% (95% CI)	% (95% CI)
Total	39.0 (31.3–46.7)	40.1 (36.7–43.6)	Total	35.5 (29.8–41.3)	33.2 (30.1–36.3)
Age (yrs)			Age (mos)		
15–24	49.0 (33.0–64.9)	39.5 (33.8–45.1)	12–23	59.4 (42.6–76.2) [§]	56.7 (49.6–63.9) [¶]
25–34	38.6 (29.6–47.6)	39.3 (34.6–44.0)	24–35	48.3 (30.9–65.6)	36.1 (30.1–42.0)
35–44	28.2 (14.7–41.7)	44.7 (36.2–53.2)	36–47	26.4 (16.4–36.4)	22.4 (16.0–28.9)
			48–59	15.0 (4.4–25.6)	18.8 (13.7–23.9)
Residence			Residence		
Urban	31.9 (20.2–41.6)	39.3 (36.1–42.6)	Urban	33.0 (24.1–41.9)	34.5 (29.8–39.1)
Rural	48.9 (41.6–56.1) [§]	41.1 (34.8–47.2)	Rural	38.5 (31.1–45.9)	32.1 (26.8–37.4)
Socioeconomic status (SES)**			SES**		
Low	48.3 (39.0–57.7) [§]	41.4 (36.1–46.8)	Low	41.0 (34.9–47.2) [§]	35.1 (31.1–39.4)
Medium-high	27.4 (17.9–36.9)	38.8 (34.1–43.4)	Medium-high	27.6 (16.8–38.3)	31.0 (26.0–35.9)
Family's housing arrangements			Family's housing arrangements		
Owned/Rented property	29.4 (18.8–40.0)	39.4 (35.5–43.3)	Owned/Rented property	31.3 (21.2–41.4)	33.9 (30.8–37.0)
Living with family or friends	35.7 (12.9–58.5)	42.1 (32.4–51.7)	Living with family or friends	29.1 (12.0–46.3)	27.7 (20.0–35.5)
Temporary housing ^{††}	47.9 (38.2–57.5)	54.8 (41.0–68.5)	Temporary housing	40.4 (32.6–48.1)	47.5 (30.5–64.4)
Education			Sex		
Primary/Incomplete secondary	64.2 (47.5–80.9) [§] §§	37.5 (29.4–45.7)	Male	38.7 (29.9–47.6)	35.3 (30.7–39.9)
Complete secondary	37.5 (28.6–46.1)	42.7 (38.0–47.4)	Female	31.1 (21.9–40.4)	31.0 (25.9–36.1)
Technicum/University	27.3 (16.5–38.1)	37.2 (31.6–42.7)			
Education of husband			Birth order		
Primary/Incomplete secondary	^{¶¶}	37.3 (21.7–53.0)	First	27.8 (16.4–39.3)	32.4 (27.0–37.8)
Complete secondary	44.1 (35.5–52.7)	40.7 (35.7–45.8)	Second	44.2 (32.2–56.2)	33.1 (28.4–37.8)
Technicum/University	33.4 (23.3–43.5)	40.0 (35.8–44.1)	Third or later	33.9 (22.5–45.3)	34.2 (29.4–39.0)
Employed			Birthweight		
Yes	33.5 (17.9–49.0)	40.4 (34.2–46.7)	<2,500 g	35.3 (23.8–46.7)	40.6 (31.8–49.3)
No	40.2 (31.9–48.5)	40.1 (35.9–44.2)	≥2,500 g	35.0 (27.6–42.3)	32.1 (28.8–35.4)
			Don't know	43.3 (18.8–67.7)	36.0 (23.3–48.6)
Husband employed			Birth interval		
Yes	31.8 (20.1–43.5)	41.3 (36.6–46.1)	First birth	27.8 (16.4–39.3)	33.4 (27.9–38.8)
No	45.7 (35.8–55.6)	38.4 (32.7–44.0)	<2 years	40.6 (27.5–53.7)	30.1 (24.4–35.6)
			≥2 years	37.8 (26.8–48.8)	35.4 (30.4–40.2)
Currently pregnant			Stunted***		
Yes	41.1 (21.4–60.8)	38.0 (24.9–51.2)	Yes	48.8 (40.6–57.0) [§]	41.9 (32.7–51.0)
No	38.8 (30.2–47.4)	40.3 (36.7–43.9)	No	32.8 (26.3–39.4)	31.8 (28.3–35.3)
Parity			Wasting^{†††}		
1	48.0 (30.3–65.8)	35.1 (28.0–42.1)	Yes	^{¶¶}	47.1 (29.3–64.6)
2	43.5 (29.3–57.8)	40.1 (34.5–45.7)	No	35.6 (29.9–41.3)	33.1 (29.8–36.1)
3	31.1 (19.0–43.1)	42.6 (36.5–48.6)			
≥4	34.4 (24.0–44.8)	44.7 (33.5–55.9)			
Family received humanitarian aid during previous year			Mother anemic		
Yes	48.2 (38.8–57.6) [§]	N/A ^{§§§}	Yes	46.5 (38.7–54.2) [§]	41.4 (36.0–46.7) [¶]
No	31.2 (21.7–40.6)	N/A	No	27.1 (20.2–33.9)	28.2 (24.3–32.0)

* Defined as a hemoglobin level of <12.0 g/dL for nonpregnant women, 11.0 g/dL for women 1–12 weeks pregnant, and 10.6, 10.5, 10.5, 10.7, 11.0, 11.4 and 11.9 g/dL, respectively, for women 16, 20, 24, 28, 32, 36, and 40 weeks pregnant. Hemoglobin cutoff levels were <11.0 g/dL for children aged 12–23 months and <11.1 g/dL for those aged 24–59 months.

† Confidence interval.

§ p<0.05 for difference within IDP/R group for that level of characteristic.

¶ p<0.05 for difference within non-IDP/R group for that level of characteristic.

** Initially represented by a score based on household amenities and goods (e.g., telephone, indoor toilet, central heat, television, refrigerator, video recorder, automobile, cellular phone, uncrowded living conditions, and recreational home/villa). Scores ranged from zero (i.e., no amenities and goods) to 10 (i.e., all amenities and goods). Respondents with scores of ≤3 were classified as having low SES, and those with scores of ≥4 as having medium-high SES.

†† Includes public buildings (e.g., schools, farms, and factories), nongovernmental shelters, railroad wagons, mud houses, dugouts, and tents.

§§ p<0.05 for difference between IDP/R and non-IDP/R groups for that level of characteristic.

¶¶ Fewer than 25 cases in this category.

*** Defined as having a height-for-age Z-score <2 standard deviations below the CDC/World Health Organization (WHO) reference.

††† Defined as having a weight-for-height Z-score <2 standard deviations below the CDC/WHO reference.

§§§ Not applicable.

Higher rates of anemia were found among IDP/R mothers receiving humanitarian aid, likely because aid was provided to those groups who were still not self-sufficient and at higher risk for anemia. The higher prevalence of anemia among other subgroups of IDP/R women and children (e.g., those in rural areas or with low SES) indicates the existence of more vulnerable groups within the general population. Special attention should be focused on improving the nutritional status of these groups through targeted interventions such as iron supplementation (7). In addition, iron fortification of staple foods like flour is a key public health intervention strategy that would benefit all mothers and children in Azerbaijan (7).

Comparing the data from the present study with the 1996 study, by using the earlier 1989 CDC criteria for defining anemia (9), indicates no significant change in overall anemia prevalence either among children (43.5% in 1996 versus 35.6% in 2001) or nonpregnant mothers (36.1% in 1996 versus 40.2% in 2001) (3,4). The lack of improvement indicates a need to enhance health intervention programs in Azerbaijan by including nutritional counseling, micronutrient supplementation, and fortification of staple foods. Because anemia is more prevalent in younger children, interventions are particularly needed among children aged <24 months, including promotion of 1) exclusive breastfeeding, 2) commercial or in-home fortification of complementary foods, and 3) dietary practices that produce improvement of iron bioavailability.

The findings in this study are subject to at least four limitations. First, the CDC Hb levels used to define anemia are based on data from the National Health and Nutrition Examination Survey of the U.S. population. These levels are higher than World Health Organization (WHO) cutoff levels, which are used primarily for developing countries and might produce overestimates of anemia prevalence. Second, higher inherent variability in capillary blood-sampling techniques used for screening anemia might introduce errors in Hb estimates. Third, enough information on food history and dietary risk factors was not collected to assess whether iron deficiency was caused by low iron intake or other factors. Finally, information on other factors (e.g., inflammation or infection) that might affect Hb levels was not available.

WHO considers anemia prevalence of $\geq 40\%$ in a population as severe and warranting immediate public health action (7); certain subgroups of mothers and children in Azerbaijan had anemia prevalence of $>40\%$. With prevalence at these

levels, WHO recommends the following daily iron supplementation regimen: for children aged 6–23 months, 2 mg/kg body weight per day; for children aged 24–59 months, 2 mg/kg body weight up to 30 mg per day for 3 months; for nonpregnant women of child-bearing age, 60 mg/day of iron and 400 μg of folic acid for 3 months; and for pregnant women, 60 mg/day of iron and 400 μg of folic acid daily throughout pregnancy.

National efforts to prevent iron deficiency should involve community, government, the private sector (e.g., food industry), and nongovernmental organizations to develop long-term strategies that incorporate behavior modification, food fortification, and integration of iron deficiency–control into ongoing public health programs. Surveillance systems should be implemented to monitor development of these strategies and track the success of interventions.

Acknowledgments

This report is based on contributions from U.S. Agency for International Development Azerbaijan; Adventist Development and Relief Agency Azerbaijan; Azerbaijan Republic Ministry of Health. United Nations Population Fund; United Nations High Commissioner for Refugees.

References

1. United Nations High Commissioner for Refugees. The state of the world's refugees: fifty years of humanitarian action. New York, New York: Oxford University Press, 2000.
2. Norwegian Refugee Council/Global IDP Project. Profile of internal displacement, Azerbaijan: global IDP database, 2002. Available at <http://www.idpproject.org>.
3. CDC. Health and nutrition survey of internally displaced and resident population of Azerbaijan. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 1996.
4. CDC. Reproductive health survey Azerbaijan, 2001: final report. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC, 2001.
5. CDC. Recommendations to prevent and control iron deficiency in the United States. MMWR 1998;47(No. RR-3).
6. U.S. Agency for International Development, CDC. Reproductive, maternal and child health in eastern Europe and Eurasia: a comparative report. Atlanta, Georgia: U.S. Agency for International Development, U.S. Department of Health and Human Services, CDC, 2003.
7. United Nations Children's Fund (UNICEF), United Nations University, World Health Organization. Iron deficiency anaemia assessment, prevention and control: a guide for programme managers. Geneva, Switzerland: World Health Organization, 2001. Available at http://www.who.int/nut/documents/ida_assessment_prevention_control.pdf.
8. Yip R. Iron deficiency: contemporary scientific issues and international programmatic approaches. J Nutr 1994;124(suppl 8):1479S–90S.
9. CDC. CDC criteria for anemia in children and childbearing-aged women. MMWR 1989;38:400–4.


West Nile Virus Activity — United States, July 7–13, 2004

During the week of July 7–13, a total of 30 human West Nile virus illness cases were reported from four states (Arizona, California, Colorado, and Iowa). During 2004, a total of 108 cases of human West Nile virus (WNV) illness to CDC through ArboNET (Table, Figure). Of these, 66 (61%) were reported from Arizona. Sixty-one (58%) of the 108 cases occurred in males; median age of patients was 52 years (range: 1–84 years); dates of illness onset ranged from April 23 to July 5; and three cases were fatal.

A total of 18 presumptive West Nile viremic blood donors (PVDs) have been reported to ArboNET. Of these, 17 were reported from Arizona, and one was reported from New Mexico. Of the 18 PVDs reported to ArboNET, two persons aged 66 and 69 years subsequently had neuroinvasive illness, and four persons aged 22, 51, 52, and 57 years subsequently had West Nile fever.

In addition, during 2004, a total of 1,080 dead corvids and 108 other dead birds with WNV infection have been reported from 29 states, and 42 WNV infections in horses have been reported from 11 states (Alabama, Arizona, California, Idaho, Missouri, North Carolina, Oklahoma, South Dakota, Tennessee, Texas, and Virginia). WNV seroconversions have been reported in 167 sentinel chicken flocks from four states (Arizona, California, Florida, and Louisiana). Three seropositive sentinel horses were reported from Puerto Rico. A total of 362 WNV-positive mosquito pools have been reported from 14 states (Arizona, California, Georgia, Illinois, Indiana,

FIGURE. Areas reporting West Nile virus (WNV) activity — United States, 2004*



* As of 3 a.m., Mountain Standard Time, July 13, 2004.

Louisiana, Michigan, Missouri, New Jersey, Ohio, Pennsylvania, Tennessee, Texas, and Virginia).

Additional information about national WNV activity is available from CDC at <http://www.cdc.gov/ncidod/dvbid/westnile/index.htm> and at <http://westnilemaps.usgs.gov>.

Update: Investigation of Rabies Infections in Organ Donor and Transplant Recipients — Alabama, Arkansas, Oklahoma, and Texas, 2004

On July 9, this report was posted as an MMWR Dispatch on the MMWR website (<http://www.cdc.gov/mmwr>).

On July 1, 2004, CDC reported laboratory confirmation of rabies as the cause of encephalitis in an organ donor and three organ recipients at Baylor University Medical Center (BUMC) in Dallas, Texas (1). Hospital and public health officials in Alabama, Arkansas, Oklahoma, and Texas initiated public health investigations to identify donor and recipient contacts, assess exposure risks, and provide rabies postexposure prophylaxis (PEP). As of July 9, PEP had been initiated in approximately 174 (19%) of 916 persons who had been assessed for exposures to the organ recipients or the donor. As a result of its public health investigation, the Arkansas Department of Health determined that the donor had reported being bitten by a bat (Frank Wilson, M.D., Arkansas Department of Health, personal communication, 2004).

On July 7, CDC was notified of an additional organ transplant patient at BUMC who had died of encephalopathy of

TABLE. Number of human cases of West Nile virus (WNV) illness, by state — United States, 2004*

State	Neuroinvasive disease [†]	West Nile fever [‡]	Other clinical/ unspecified [§]	Total reported to CDC**	Deaths
Arizona	47	12	7	66	2
California	9	11	0	20	0
Colorado	1	11	0	12	0
Florida	1	1	0	2	0
Iowa	1	0	0	1	1
Michigan	1	0	0	1	0
Nebraska	0	1	0	1	0
New Mexico	0	3	0	3	0
South Dakota	1	0	0	1	0
Wyoming	0	1	0	1	0
Total	61	40	7	108	3

* As of July 13, 2004.

[†] Cases with neurologic manifestations (e.g., West Nile meningitis, West Nile encephalitis, and West Nile myelitis).

[‡] Cases with no evidence of neuroinvasion.

[§] Illnesses for which sufficient clinical information was not provided.

** Total number of human cases of WNV illness reported to ArboNet by state and local health departments.

unknown origin in early June. This case was detected as part of an ongoing review of transplant-patient autopsies. The patient, who had end-stage liver disease, had received a liver transplant at BUMC in early May 2004. The patient remained hospitalized with transplant-related complications and began having neurologic abnormalities in early June, progressing to seizure, coma, and death. On July 7, pathologists at BUMC identified intracytoplasmic inclusions, suggestive of rabies, in neurons in multiple areas of the brain.

Specimens from the recipient were sent to CDC on July 7, and direct fluorescent antibody and immunohistochemical staining procedures confirmed the presence of rabies viral antigens in multiple areas of the brain, including the hippocampus, midbrain, pons, medulla, and cerebellum. Similar to the findings with the three previously known rabies-infected transplant recipients, preliminary antigenic characterization of the agent was consistent with a rabies virus variant associated with insectivorous bats. On July 8, CDC laboratory testing of tissues and serum from the donor who provided the liver yielded no evidence of infection with rabies virus.

Review of surgical procedures at BUMC determined that a segment of iliac artery recovered from the donor subsequently

determined to have rabies had been stored at the facility for future use in liver transplants. This artery segment subsequently was used in the transplantation of the liver in the most recently identified rabies-infected recipient. Investigation of rabies transmission sources is ongoing, although current evidence suggests that the artery segment originating from the rabies-infected donor likely is the source of the latest rabies infection. Identification of contacts of this liver recipient is under way, and initiation of PEP when indicated or as appropriate is in progress.

Reference

1. CDC. Investigation of rabies infections in organ donor and transplant recipients—Alabama, Arkansas, Oklahoma, and Texas, 2004. *MMWR* 2004;53:586–9.

Erratum: Vol. 53, No. 26

In the notice to readers, "Updated Recommendations for Use of Pneumococcal Conjugate Vaccine: Reinstatement of the Third Dose," an error occurred on page 590; an incorrect telephone number was provided for the customer service department at Wyeth Vaccines. The correct number is 800-666-7248.


e ncore.

Week after week, MMWR Online plays an important role in helping you stay informed. From the latest CDC guidance to breaking health news, count on MMWR Online to deliver the news you need, when you need it.

Log on to cdc.gov/mmwr and enjoy MMWR performance.

know what matters.



FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals July 10, 2004, with historical data

* No rubella cases were reported for the current 4-week period yielding a ratio for week 27 of zero (0).

[†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending July 10, 2004 (27th Week)*

	Cum. 2004	Cum. 2003		Cum. 2004	Cum. 2003
Anthrax	-	-	Hemolytic uremic syndrome, postdiarrheal [†]	49	63
Botulism:	-	-	HIV infection, pediatric ^{†§}	78	125
foodborne	7	7	Measles, total	15**	31 ^{††}
infant	38	33	Mumps	106	120
other (wound & unspecified)	5	10	Plague	-	1
Brucellosis [†]	59	45	Poliomyelitis, paralytic	-	-
Chancroid	17	29	Psittacosis [†]	4	6
Cholera	2	1	Q fever [†]	25	42
Cyclosporiasis [†]	67	33	Rabies, human	1	-
Diphtheria	-	-	Rubella	13	6
Ehrlichiosis:	-	-	Rubella, congenital syndrome	-	1
human granulocytic (HGE) [†]	63	82	SARS-associated coronavirus disease ^{† §§}	-	7
human monocytic (HME) [†]	55	67	Smallpox ^{† ¶¶}	-	NA
human, other and unspecified	3	14	<i>Staphylococcus aureus</i> :	-	-
Encephalitis/Meningitis:	-	-	Vancomycin-intermediate (VISA) ^{† ¶¶}	4	NA
California serogroup viral ^{† §}	2	8	Vancomycin-resistant (VRSA) ^{† ¶¶}	1	1
eastern equine ^{† §}	-	3	Streptococcal toxic-shock syndrome [†]	61	115
Powassan ^{† §}	-	-	Tetanus	6	4
St. Louis ^{† §}	1	2	Toxic-shock syndrome	52	71
western equine ^{† §}	-	-	Trichinosis	2	-
Hansen disease (leprosy) [†]	38	40	Tularemia [†]	31	26
Hantavirus pulmonary syndrome [†]	7	14	Yellow fever	-	-

-: No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

[†] Not notifiable in all states.

[§] Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance).

^{¶¶} Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update May 23, 2004.

** Of 15 cases reported, eight were indigenous, and seven were imported from another country.

^{††} Of 31 cases reported, 22 were indigenous, and nine were imported from another country.

^{§§} Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases (notifiable as of July 2003).

^{¶¶} Not previously notifiable.

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	AIDS		Chlamydia†		Coccidioidomycosis		Cryptosporidiosis		Encephalitis/Meningitis West Nile‡	
	Cum. 2004†	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
UNITED STATES	17,011	22,896	431,644	440,085	2,777	1,548	1,162	1,048	60	40
NEW ENGLAND	569	784	14,572	14,096	-	-	66	74	-	-
Maine	5	35	1,013	975	N	N	13	6	-	-
N.H.	23	18	848	800	-	-	16	10	-	-
Vt.	13	6	531	518	-	-	7	13	-	-
Mass.	150	326	7,003	5,515	-	-	19	33	-	-
R.I.	66	63	1,674	1,554	-	-	2	9	-	-
Conn.	312	336	3,503	4,734	N	N	9	3	-	-
MID. ATLANTIC	3,912	5,062	55,468	54,639	-	-	177	146	-	4
Upstate N.Y.	453	615	11,452	9,836	N	N	47	37	-	-
N.Y. City	2,154	2,315	16,198	18,034	-	-	43	50	-	-
N.J.	675	929	6,307	7,973	-	-	11	9	-	-
Pa.	630	1,203	21,511	18,796	N	N	76	50	-	4
E.N. CENTRAL	1,455	2,374	73,782	79,726	7	3	267	259	1	5
Ohio	237	419	19,559	21,331	-	-	76	38	-	3
Ind.	166	305	9,241	8,803	N	N	37	27	-	2
Ill.	700	1,118	18,084	24,946	-	-	13	38	-	-
Mich.	269	417	18,931	15,870	7	3	64	48	1	-
Wis.	83	115	7,967	8,776	-	-	77	108	-	-
W.N. CENTRAL	331	410	25,880	25,184	4	2	165	109	1	5
Minn.	81	77	4,781	5,497	N	N	57	44	-	1
Iowa	21	45	2,311	2,833	N	N	30	18	-	2
Mo.	135	203	10,253	9,107	3	1	24	10	-	-
N. Dak.	12	1	769	801	N	N	8	7	-	-
S. Dak.	5	6	1,281	1,247	-	-	22	21	1	1
Nebr.**	18	30	2,693	2,139	1	1	12	4	-	1
Kans.	59	48	3,792	3,560	N	N	12	5	-	-
S. ATLANTIC	5,282	6,438	81,978	81,899	-	3	220	148	1	2
Del.	78	133	1,472	1,587	N	N	-	3	-	-
Md.	601	729	9,665	8,378	-	3	10	8	-	-
D.C.	308	656	1,562	1,693	-	-	3	3	-	-
Va.	288	507	11,084	9,720	-	-	24	14	-	-
W. Va.	30	49	1,437	1,284	N	N	3	3	-	-
N.C.	305	630	14,603	13,283	N	N	38	18	-	-
S.C.**	329	435	7,657	6,788	-	-	9	2	-	1
Ga.	782	953	12,863	17,704	-	-	70	55	-	-
Fla.	2,561	2,346	21,635	21,462	N	N	63	42	1	1
E.S. CENTRAL	782	982	27,527	28,445	2	1	46	59	-	3
Ky.	71	83	2,868	4,261	N	N	16	12	-	-
Tenn.**	326	437	11,576	10,027	N	N	12	21	-	-
Ala.	208	249	5,358	7,721	-	-	11	23	-	3
Miss.	177	213	7,725	6,436	2	1	7	3	-	-
W.S. CENTRAL	2,047	2,352	56,093	54,807	2	-	36	23	-	16
Ark.	87	86	3,959	3,918	1	-	11	3	-	-
La.	346	400	11,986	10,688	1	-	-	1	-	5
Okla.	90	109	5,933	5,502	N	N	12	5	-	-
Tex.	1,524	1,757	34,215	34,699	-	-	13	14	-	11
MOUNTAIN	571	886	21,719	26,084	1,721	997	59	51	48	5
Mont.	-	10	1,054	1,111	N	N	11	12	-	-
Idaho	3	15	1,487	1,227	N	N	5	8	-	-
Wyo.	6	5	544	496	-	-	2	2	-	1
Colo.	98	211	4,656	6,589	N	N	26	11	1	4
N. Mex.	91	62	2,586	3,900	9	4	2	3	-	-
Ariz.	208	392	7,673	7,775	1,668	970	10	3	47	-
Utah	34	39	1,749	1,892	15	3	2	9	-	-
Nev.	131	152	1,970	3,094	29	20	1	3	-	-
PACIFIC	2,062	3,608	74,625	75,205	1,041	542	126	179	9	-
Wash.	165	247	9,106	8,081	N	N	14	14	-	-
Oreg.	111	145	4,248	3,973	1	-	16	21	-	-
Calif.	1,731	3,144	58,051	58,434	1,040	542	95	144	9	-
Alaska	14	13	1,891	1,975	-	-	-	-	-	-
Hawaii	41	59	1,329	2,742	-	-	1	-	-	-
Guam	1	5	-	365	-	-	-	-	-	-
P.R.	209	620	1,002	1,249	N	N	N	N	-	-
V.I.	5	17	143	175	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	2	U	32	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases. C.N.M.I.: Commonwealth of Northern Mariana Islands.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

† Chlamydia refers to genital infections caused by *C. trachomatis*.

‡ Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases (ArboNet Surveillance).

* Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update May 30, 2004.

** Contains data reported through National Electronic Disease Surveillance System (NEDSS).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	<i>Escherichia coli</i> , Enterohemorrhagic (EHEC)						Giardiasis		Gonorrhea	
	O157:H7		Shiga toxin positive, serogroup non-O157		Shiga toxin positive, not serogrouped		Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003				
UNITED STATES	784	738	90	94	70	58	7,418	7,977	149,130	164,203
NEW ENGLAND	53	40	26	18	13	2	679	579	3,383	3,482
Maine	2	4	-	-	-	-	68	60	131	116
N.H.	10	7	5	2	-	-	16	22	62	58
Vt.	4	3	-	-	1	-	64	43	44	41
Mass.	25	14	3	6	12	2	301	285	1,597	1,335
R.I.	5	1	1	-	-	-	54	55	461	474
Conn.	7	11	17	10	-	-	176	114	1,088	1,458
MID. ATLANTIC	94	87	11	8	13	13	1,674	1,673	17,500	20,866
Upstate N.Y.	45	31	6	4	4	6	570	420	3,723	3,751
N.Y. City	13	3	-	-	-	-	529	585	5,152	6,918
N.J.	14	12	3	1	4	-	169	237	2,531	4,455
Pa.	22	41	2	3	5	7	406	431	6,094	5,742
E.N. CENTRAL	154	193	17	18	9	9	881	1,433	29,854	34,643
Ohio	44	43	4	10	9	9	369	404	9,272	11,032
Ind.	13	28	-	-	-	-	-	-	3,190	3,283
Ill.	28	33	-	1	-	-	84	451	7,708	10,807
Mich.	34	32	3	-	-	-	292	322	7,601	6,545
Wis.	35	57	10	7	-	-	136	256	2,083	2,976
W.N. CENTRAL	164	113	15	17	14	9	878	798	8,278	8,415
Minn.	33	40	6	8	2	-	308	297	1,654	1,372
Iowa	49	17	-	-	-	-	124	109	412	661
Mo.	30	32	9	2	5	1	224	230	4,194	4,302
N. Dak.	4	4	-	3	5	2	15	19	60	35
S. Dak.	11	6	-	3	-	-	32	21	139	99
Nebr.	23	5	-	1	-	-	64	56	528	683
Kans.	14	9	-	-	2	6	111	66	1,291	1,263
S. ATLANTIC	66	55	11	21	13	14	1,224	1,198	36,293	39,868
Del.	1	-	N	N	N	N	26	19	472	600
Md.	15	3	1	1	1	1	50	55	4,167	3,892
D.C.	1	1	-	-	-	-	33	18	1,124	1,246
Va.	9	17	6	4	-	-	186	161	4,406	4,424
W. Va.	1	2	-	-	-	-	14	14	442	433
N.C.	-	-	-	-	6	13	N	N	7,837	7,478
S.C.	3	-	-	-	-	-	27	64	3,564	3,880
Ga.	15	12	2	3	-	-	344	382	5,427	8,545
Fla.	21	20	2	13	6	-	544	485	8,854	9,370
E.S. CENTRAL	37	32	1	-	7	4	158	166	11,737	13,824
Ky.	14	10	1	-	4	4	N	N	1,259	1,793
Tenn.	8	13	-	-	3	-	74	76	4,202	4,066
Ala.	8	6	-	-	-	-	84	90	3,277	4,719
Miss.	7	3	-	-	-	-	-	-	2,999	3,246
W.S. CENTRAL	40	33	1	2	1	3	126	139	20,866	22,374
Ark.	7	4	-	-	-	-	54	75	1,934	2,123
La.	2	1	-	-	-	-	18	8	5,368	6,124
Okla.	9	8	-	-	-	-	54	56	2,456	2,105
Tex.	22	20	1	2	1	3	-	-	11,108	12,022
MOUNTAIN	66	79	7	8	-	4	599	636	4,788	5,512
Mont.	3	2	-	-	-	-	19	35	36	57
Idaho	18	18	3	5	-	-	77	75	42	37
Wyo.	-	2	1	-	-	-	9	9	29	24
Colo.	14	23	1	1	-	4	197	187	1,364	1,498
N. Mex.	4	2	-	2	-	-	33	25	313	645
Ariz.	8	16	N	N	N	N	89	110	1,870	2,027
Utah	12	11	1	-	-	-	134	133	261	178
Nev.	7	5	1	-	-	-	41	62	873	1,046
PACIFIC	110	106	1	2	-	-	1,199	1,355	16,431	15,219
Wash.	37	28	-	1	-	-	151	131	1,372	1,461
Oreg.	14	19	1	1	-	-	199	176	553	533
Calif.	51	58	-	-	-	-	773	963	13,882	12,387
Alaska	1	1	-	-	-	-	32	42	300	280
Hawaii	7	-	-	-	-	-	44	43	324	558
Guam	N	N	-	-	-	-	-	-	-	38
P.R.	-	1	-	-	-	-	13	110	91	143
V.I.	-	-	-	-	-	-	-	-	49	43
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	-	U	3	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	<i>Haemophilus influenzae</i> , invasive								Hepatitis (viral, acute), by type	
	All ages		Age <5 years						A	
	All serotypes		Serotype b		Non-serotype b		Unknown serotype			
	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
UNITED STATES	1,039	1,004	9	15	49	70	104	118	2,726	3,233
NEW ENGLAND	95	67	1	1	5	5	3	3	447	143
Maine	7	2	-	-	-	-	-	1	9	5
N.H.	13	7	-	-	2	-	-	-	10	9
Vt.	5	6	-	-	-	-	1	-	8	4
Mass.	40	37	1	1	-	5	2	1	379	71
R.I.	3	4	-	-	-	-	-	1	10	11
Conn.	27	11	-	-	3	-	-	-	31	43
MID. ATLANTIC	219	203	-	1	3	2	26	28	303	686
Upstate N.Y.	75	70	-	1	3	2	3	7	43	57
N.Y. City	45	35	-	-	-	-	9	6	107	252
N.J.	40	43	-	-	-	-	3	7	61	111
Pa.	59	55	-	-	-	-	11	8	92	266
E.N. CENTRAL	165	169	-	2	6	3	25	32	239	325
Ohio	68	43	-	-	2	-	10	7	27	62
Ind.	32	26	-	-	4	-	1	2	15	28
Ill.	36	65	-	-	-	-	8	17	90	94
Mich.	13	13	-	2	-	3	5	1	85	109
Wis.	16	22	-	-	-	-	1	5	22	32
W.N. CENTRAL	64	67	2	-	3	6	4	7	101	84
Minn.	27	24	1	-	3	6	-	1	23	20
Iowa	1	-	1	-	-	-	-	-	30	16
Mo.	21	28	-	-	-	-	2	6	30	27
N. Dak.	3	2	-	-	-	-	-	-	1	-
S. Dak.	-	1	-	-	-	-	-	-	2	-
Nebr.	5	1	-	-	-	-	-	-	7	7
Kans.	7	11	-	-	-	-	2	-	8	14
S. ATLANTIC	253	197	-	-	15	8	20	12	521	692
Del.	8	-	-	-	-	-	2	-	5	4
Md.	41	45	-	-	3	4	1	-	74	68
D.C.	-	-	-	-	-	-	-	-	4	24
Va.	22	23	-	-	-	-	1	4	51	43
W. Va.	10	7	-	-	-	-	3	-	2	10
N.C.	37	17	-	-	5	1	1	1	35	33
S.C.	2	2	-	-	-	-	-	-	20	23
Ga.	69	40	-	-	-	-	12	4	184	280
Fla.	64	63	-	-	7	3	-	3	146	207
E.S. CENTRAL	37	43	-	1	-	2	7	4	82	89
Ky.	3	3	-	-	-	1	-	-	12	17
Tenn.	23	24	-	-	-	1	5	3	46	48
Ala.	11	16	-	1	-	-	2	1	6	11
Miss.	-	-	-	-	-	-	-	-	18	13
W.S. CENTRAL	44	49	1	1	4	7	1	4	211	323
Ark.	1	5	-	-	-	1	-	-	38	19
La.	7	16	-	-	-	2	1	4	13	30
Okla.	35	26	-	-	4	4	-	-	17	6
Tex.	1	2	1	1	-	-	-	-	143	268
MOUNTAIN	122	113	3	6	13	18	13	12	248	239
Mont.	-	-	-	-	-	-	-	-	4	2
Idaho	5	3	-	-	-	-	2	1	10	9
Wyo.	-	1	-	-	-	-	-	-	3	1
Colo.	28	20	-	-	-	-	3	4	25	33
N. Mex.	24	14	-	-	4	3	3	1	8	11
Ariz.	47	60	-	6	7	8	1	4	159	133
Utah	10	9	2	-	1	4	2	2	33	17
Nev.	8	6	1	-	1	3	2	-	6	33
PACIFIC	40	96	2	3	-	19	5	16	574	652
Wash.	3	5	2	-	-	4	1	1	32	35
Oreg.	26	24	-	-	-	-	1	2	40	35
Calif.	3	42	-	3	-	15	2	8	484	572
Alaska	4	18	-	-	-	-	1	5	4	6
Hawaii	4	7	-	-	-	-	-	-	14	4
Guam	-	-	-	-	-	-	-	-	-	1
P.R.	-	-	-	-	-	-	-	-	10	42
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	Hepatitis (viral, acute), by type				Legionellosis		Listeriosis		Lyme disease	
	B		C		Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003						
UNITED STATES	2,992	3,484	592	552	638	754	247	277	4,701	6,455
NEW ENGLAND	167	171	4	3	13	28	11	14	552	953
Maine	1	1	-	-	-	1	3	2	53	-
N.H.	22	11	-	-	-	4	1	2	48	16
Vt.	2	2	1	3	1	1	-	-	13	9
Mass.	89	118	3	-	4	12	2	8	154	636
R.I.	3	4	-	-	2	2	1	-	72	121
Conn.	50	35	U	U	6	8	4	2	212	171
MID. ATLANTIC	516	422	57	68	152	173	52	50	3,430	4,482
Upstate N.Y.	47	39	6	9	36	40	22	10	1,288	1,212
N.Y. City	51	134	-	-	11	16	6	11	-	83
N.J.	277	110	-	-	34	22	10	10	919	1,426
Pa.	141	139	51	59	71	95	14	19	1,223	1,761
E.N. CENTRAL	246	269	35	85	165	153	39	35	889	984
Ohio	70	77	3	6	89	77	17	7	38	22
Ind.	8	15	2	3	13	9	8	1	2	7
Ill.	33	34	5	14	10	18	-	11	-	34
Mich.	135	115	25	58	51	37	13	11	7	-
Wis.	-	28	-	4	2	12	1	5	42	321
W.N. CENTRAL	206	154	201	119	15	34	6	8	97	85
Minn.	21	19	4	3	1	3	2	2	39	53
Iowa	9	4	-	-	3	5	1	-	9	11
Mo.	143	106	197	115	9	16	2	3	41	17
N. Dak.	3	-	-	-	1	1	-	-	-	-
S. Dak.	-	2	-	-	1	1	-	-	-	-
Nebr.	16	14	-	1	-	2	1	3	5	2
Kans.	14	9	-	-	-	6	-	-	3	2
S. ATLANTIC	944	930	100	84	159	210	36	56	445	423
Del.	19	6	-	-	4	6	N	N	46	83
Md.	81	56	13	6	30	46	4	7	271	269
D.C.	13	1	1	-	5	1	-	-	2	4
Va.	111	78	11	2	16	37	6	7	34	21
W. Va.	4	10	17	1	3	3	1	2	2	3
N.C.	92	95	6	5	15	16	8	10	49	20
S.C.	53	80	7	17	1	5	-	2	5	1
Ga.	296	290	7	6	21	19	7	16	7	9
Fla.	275	314	38	47	64	77	10	12	29	13
E.S. CENTRAL	212	225	57	43	28	53	17	10	26	26
Ky.	26	40	16	7	9	22	4	1	11	5
Tenn.	95	92	25	9	10	17	8	1	9	8
Ala.	33	43	1	5	8	11	3	6	1	1
Miss.	58	50	15	22	1	3	2	2	5	12
W.S. CENTRAL	94	563	74	96	34	35	18	32	13	59
Ark.	28	50	1	3	-	2	1	1	2	-
La.	30	76	40	57	3	1	2	1	1	6
Okla.	19	34	2	1	2	4	-	1	-	-
Tex.	17	403	31	35	29	28	15	29	10	53
MOUNTAIN	254	306	29	20	38	35	11	17	10	5
Mont.	2	8	2	1	1	2	-	1	-	-
Idaho	6	4	-	1	4	3	1	-	2	2
Wyo.	7	18	4	-	4	2	-	-	2	-
Colo.	21	46	4	5	5	7	3	6	-	-
N. Mex.	10	23	6	-	-	2	-	2	-	1
Ariz.	145	147	3	4	10	9	-	5	1	-
Utah	28	20	2	-	12	7	1	2	5	1
Nev.	35	40	8	9	2	3	6	1	-	1
PACIFIC	353	444	35	34	34	33	57	55	39	38
Wash.	28	36	10	11	6	4	6	3	3	-
Oreg.	53	69	9	5	N	N	4	2	16	8
Calif.	258	325	13	17	28	29	46	47	20	29
Alaska	12	3	-	-	-	-	-	-	-	1
Hawaii	2	11	3	1	-	-	1	3	N	N
Guam	-	3	-	1	-	-	-	-	-	-
P.R.	19	70	-	-	1	-	-	-	N	N
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	Malaria		Meningococcal disease		Pertussis		Rabies, animal		Rocky Mountain spotted fever	
	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
UNITED STATES	536	510	798	1,010	4,690	3,646	2,487	3,593	392	254
NEW ENGLAND	43	14	38	47	658	379	263	241	10	3
Maine	5	1	8	5	2	4	29	22	-	-
N.H.	-	2	3	3	24	22	10	10	-	-
Vt.	3	-	1	-	40	31	10	16	-	-
Mass.	20	11	21	30	564	296	106	93	9	3
R.I.	2	-	1	2	16	7	15	30	1	-
Conn.	13	-	4	7	12	19	93	70	-	-
MID. ATLANTIC	122	123	96	124	1,201	367	232	433	27	18
Upstate N.Y.	19	24	23	27	875	149	199	166	1	-
N.Y. City	56	61	17	29	73	54	4	5	4	6
N.J.	22	21	21	18	96	65	-	62	9	9
Pa.	25	17	35	50	157	99	29	200	13	3
E.N. CENTRAL	41	53	109	161	681	281	24	41	16	7
Ohio	15	10	44	43	225	114	9	16	8	3
Ind.	3	1	15	27	48	28	4	2	5	-
Ill.	3	26	12	46	132	20	9	6	-	2
Mich.	13	13	31	25	61	31	2	15	3	2
Wis.	7	3	7	20	215	88	-	2	-	-
W.N. CENTRAL	36	24	56	76	375	160	249	364	45	16
Minn.	18	12	14	17	75	56	26	15	-	-
Iowa	1	3	11	15	33	41	38	46	-	2
Mo.	7	3	17	30	178	31	15	3	38	12
N. Dak.	2	-	1	1	54	2	35	34	-	-
S. Dak.	1	1	2	1	9	2	10	77	-	-
Nebr.	2	-	2	5	3	3	53	69	6	2
Kans.	5	5	9	7	23	25	72	120	1	-
S. ATLANTIC	148	121	152	174	287	251	911	1,448	165	156
Del.	3	-	9	8	5	2	9	23	-	-
Md.	30	32	7	17	58	37	50	217	19	45
D.C.	8	7	4	3	2	-	-	-	-	-
Va.	12	8	10	18	85	58	233	284	7	3
W. Va.	-	4	4	1	5	5	32	45	1	3
N.C.	9	8	23	19	46	74	347	415	110	60
S.C.	7	3	12	14	26	15	75	84	8	9
Ga.	26	27	10	19	8	20	159	192	11	32
Fla.	53	32	73	75	52	40	6	188	9	4
E.S. CENTRAL	18	9	34	46	58	81	65	114	53	42
Ky.	1	1	4	8	11	18	13	21	-	-
Tenn.	3	4	10	12	30	44	21	80	25	25
Ala.	11	2	10	12	11	12	28	12	14	4
Miss.	3	2	10	14	6	7	3	1	14	13
W.S. CENTRAL	48	64	80	118	276	251	593	765	64	8
Ark.	6	4	12	10	9	12	28	25	34	-
La.	2	2	22	31	6	7	-	1	3	-
Okla.	2	2	4	10	17	24	70	134	27	2
Tex.	38	56	42	67	244	208	495	605	-	6
MOUNTAIN	19	16	35	53	519	539	58	77	8	4
Mont.	-	-	3	2	14	1	8	11	2	1
Idaho	1	1	4	6	18	34	-	3	1	1
Wyo.	-	-	2	2	3	119	-	1	1	2
Colo.	6	11	9	12	264	187	9	11	-	-
N. Mex.	1	-	5	7	64	33	2	5	1	-
Ariz.	4	2	6	20	109	96	39	40	1	-
Utah	5	1	3	-	37	51	-	4	2	-
Nev.	2	1	3	4	10	18	-	2	-	-
PACIFIC	61	86	198	211	635	1,337	92	110	4	-
Wash.	4	12	19	17	341	297	-	-	-	-
Oreg.	9	7	41	33	243	247	2	4	2	-
Calif.	47	64	133	148	35	786	82	101	2	-
Alaska	-	-	1	4	8	1	8	5	-	-
Hawaii	1	3	4	9	8	6	-	-	-	-
Guam	-	-	-	-	-	1	-	-	-	-
P.R.	-	-	4	6	2	1	30	35	N	N
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	-	U	-	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	Salmonellosis		Shigellosis		Streptococcal disease, invasive, group A		Streptococcus pneumoniae, invasive			
							Drug resistant, all ages		Age <5 years	
	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
UNITED STATES	14,478	16,830	5,141	11,623	2,827	3,713	1,279	1,259	320	438
NEW ENGLAND	722	855	120	146	134	341	15	67	7	5
Maine	37	55	2	6	6	20	2	-	1	-
N.H.	44	58	5	4	15	21	-	-	-	-
Vt.	24	31	2	5	8	16	7	6	N	N
Mass.	416	506	75	95	88	147	N	N	1	2
R.I.	48	40	8	4	17	5	6	N	N	N
Conn.	153	165	28	32	-	132	-	51	5	3
MID. ATLANTIC	1,831	1,994	604	1,197	457	651	95	82	68	65
Upstate N.Y.	472	419	295	160	160	240	46	41	48	47
N.Y. City	514	539	170	194	67	92	U	U	U	U
N.J.	303	356	87	201	90	130	-	-	2	2
Pa.	542	680	52	642	140	189	49	41	18	16
E.N. CENTRAL	1,794	2,493	361	994	571	909	312	282	94	188
Ohio	551	627	80	167	159	211	227	188	56	65
Ind.	188	233	87	65	69	80	83	94	21	16
Ill.	321	969	87	552	127	234	-	-	-	73
Mich.	391	337	54	139	189	265	2	-	N	N
Wis.	343	327	53	71	27	119	N	N	17	34
W.N. CENTRAL	1,105	973	183	363	194	227	10	9	42	50
Minn.	247	238	23	45	97	110	-	-	31	34
Iowa	220	164	38	23	N	N	N	N	N	N
Mo.	319	321	78	189	41	49	7	6	4	2
N. Dak.	19	21	2	5	9	10	-	3	1	4
S. Dak.	50	36	7	8	8	18	3	-	-	-
Nebr.	72	69	8	60	10	20	-	-	4	5
Kans.	178	124	27	33	29	20	N	N	2	5
S. ATLANTIC	3,390	3,779	1,348	3,630	555	608	648	669	11	12
Del.	18	44	3	144	3	6	4	1	N	N
Md.	307	371	56	280	117	153	-	4	-	-
D.C.	17	15	20	31	5	5	3	-	3	4
Va.	380	376	59	197	43	77	N	N	N	N
W. Va.	68	43	-	-	16	27	73	40	8	8
N.C.	389	508	138	449	84	66	N	N	U	U
S.C.	208	192	185	227	35	30	54	100	N	N
Ga.	547	636	311	770	115	121	150	151	N	N
Fla.	1,456	1,594	576	1,532	137	123	364	373	N	N
E.S. CENTRAL	913	1,041	289	507	134	129	77	92	-	-
Ky.	153	170	39	58	45	34	20	11	N	N
Tenn.	217	323	109	179	89	95	57	81	N	N
Ala.	252	250	111	161	-	-	-	-	N	N
Miss.	291	298	30	109	-	-	-	-	N	N
W.S. CENTRAL	1,294	2,411	1,186	3,233	160	172	34	50	67	68
Ark.	226	248	33	51	9	5	6	17	7	4
La.	196	334	125	260	1	1	28	33	8	14
Okla.	154	158	261	467	43	55	N	N	30	31
Tex.	718	1,671	767	2,455	107	111	N	N	22	19
MOUNTAIN	1,027	994	375	473	335	324	19	4	31	50
Mont.	64	49	4	2	-	1	-	-	-	-
Idaho	70	93	6	11	5	12	N	N	N	N
Wyo.	23	48	1	1	6	1	5	3	-	-
Colo.	249	246	64	72	85	85	-	-	28	38
N. Mex.	102	97	59	100	59	83	5	-	-	8
Ariz.	339	287	201	236	151	121	N	N	N	N
Utah	105	97	20	24	28	20	7	1	3	4
Nev.	75	77	20	27	1	1	2	-	-	-
PACIFIC	2,402	2,290	675	1,080	287	352	69	4	-	-
Wash.	241	266	56	87	34	29	-	-	N	N
Oreg.	195	206	34	49	N	N	N	N	N	N
Calif.	1,740	1,676	558	923	203	259	N	N	N	N
Alaska	37	48	4	4	-	-	-	-	N	N
Hawaii	189	94	23	17	50	64	69	4	-	-
Guam	-	24	-	22	-	-	-	-	-	-
P.R.	81	296	1	5	N	N	N	N	N	N
V.I.	-	-	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	3	U	-	U	-	U	-	U	-	U

N: Not notifiable. U: Unavailable. - : No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending July 10, 2004, and July 5, 2003 (27th Week)*

Reporting area	Syphilis				Tuberculosis		Typhoid fever		Varicella (Chickenpox)	
	Primary & secondary		Congenital		Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003
	Cum. 2004	Cum. 2003	Cum. 2004	Cum. 2003						
UNITED STATES	3,622	3,624	168	238	4,751	6,222	120	161	8,723	9,737
NEW ENGLAND	98	112	1	-	188	208	13	17	583	2,126
Maine	2	4	-	-	-	11	-	-	179	634
N.H.	3	13	-	-	8	10	-	1	-	-
Vt.	-	-	-	-	-	5	-	-	404	483
Mass.	64	71	-	-	118	98	11	9	-	104
R.I.	14	12	-	-	17	26	1	2	-	3
Conn.	15	12	1	-	45	58	1	5	-	902
MID. ATLANTIC	516	419	28	38	1,001	1,103	30	25	33	12
Upstate N.Y.	45	17	2	5	116	118	3	3	-	-
N.Y. City	269	237	9	21	533	599	8	13	-	-
N.J.	83	81	17	12	204	200	9	8	-	-
Pa.	119	84	-	-	148	186	10	1	33	12
E.N. CENTRAL	387	506	33	42	567	575	6	19	3,837	3,716
Ohio	119	107	1	2	104	96	2	-	997	920
Ind.	29	24	8	8	71	67	-	4	-	-
Ill.	121	216	2	16	250	271	-	8	-	-
Mich.	104	148	22	16	105	110	3	7	2,493	2,233
Wis.	14	11	-	-	37	31	1	-	347	563
W.N. CENTRAL	73	93	1	4	216	234	3	4	117	39
Minn.	12	31	-	-	82	88	2	2	-	-
Iowa	4	7	-	-	19	12	-	1	N	N
Mo.	37	31	-	4	61	64	1	1	2	-
N. Dak.	-	-	-	-	3	-	-	-	72	39
S. Dak.	-	1	-	-	5	13	-	-	43	-
Nebr.	4	3	-	-	15	10	-	-	-	-
Kans.	16	20	1	-	31	47	-	-	-	-
S. ATLANTIC	958	958	21	47	906	1,187	23	30	1,440	1,394
Del.	3	4	1	-	-	-	-	-	4	15
Md.	185	152	3	8	128	115	5	7	-	-
D.C.	38	29	1	-	-	-	-	-	17	18
Va.	54	43	1	1	105	110	3	11	355	350
W. Va.	2	1	-	-	12	10	-	-	847	846
N.C.	85	87	4	9	125	145	3	5	N	N
S.C.	53	59	1	4	104	83	-	-	217	165
Ga.	147	257	1	12	11	264	9	3	-	-
Fla.	391	326	9	13	421	460	3	4	-	-
E.S. CENTRAL	201	170	11	8	300	330	4	2	2	-
Ky.	24	21	1	1	54	59	2	-	-	-
Tenn.	75	70	5	2	106	101	2	1	-	-
Ala.	84	63	3	4	107	117	-	1	-	-
Miss.	18	16	2	1	33	53	-	-	2	-
W.S. CENTRAL	586	418	28	37	314	968	7	11	1,168	2,105
Ark.	20	24	-	1	63	49	-	-	-	-
La.	107	56	-	-	-	-	-	-	42	9
Okla.	18	25	2	1	75	69	-	-	-	-
Tex.	441	313	26	35	176	850	7	11	1,126	2,096
MOUNTAIN	181	158	30	23	200	190	5	4	1,543	345
Mont.	-	-	-	-	4	-	-	-	-	-
Idaho	13	4	2	-	-	3	-	-	-	-
Wyo.	1	-	-	-	1	2	-	-	21	37
Colo.	19	21	-	3	50	45	1	3	1,157	-
N. Mex.	26	32	1	4	13	28	-	-	67	-
Ariz.	109	93	27	16	110	76	2	1	-	-
Utah	3	2	-	-	22	15	1	-	298	308
Nev.	10	6	-	-	-	21	1	-	-	-
PACIFIC	622	790	15	39	1,059	1,427	29	49	-	-
Wash.	51	38	-	-	122	114	2	2	-	-
Oreg.	16	25	-	-	34	55	1	2	-	-
Calif.	552	720	15	39	828	1,179	20	45	-	-
Alaska	-	1	-	-	15	28	-	-	-	-
Hawaii	3	6	-	-	60	51	6	-	-	-
Guam	-	1	-	-	-	30	-	-	-	84
P.R.	54	107	2	8	14	49	-	-	150	285
V.I.	4	1	-	-	-	-	-	-	-	-
Amer. Samoa	U	U	U	U	U	U	U	U	U	U
C.N.M.I.	2	U	-	U	10	U	-	U	-	U

N: Not notifiable. U: Unavailable. -: No reported cases.

* Incidence data for reporting years 2003 and 2004 are provisional and cumulative (year-to-date).

TABLE III. Deaths in 122 U.S. cities,* week ending July 10, 2004 (27th Week)

All causes, by age (years)								All causes, by age (years)								
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I [†] Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	P&I [†] Total	
NEW ENGLAND	411	291	78	27	9	6	35	S. ATLANTIC	1,055	616	281	95	29	34	34	
Boston, Mass.	113	72	19	13	3	6	8	Atlanta, Ga.	203	110	56	26	5	6	3	
Bridgeport, Conn.	42	32	6	2	2	-	2	Baltimore, Md.	133	78	36	13	5	1	7	
Cambridge, Mass.	15	13	1	1	-	-	1	Charlotte, N.C.	76	48	13	9	2	4	6	
Fall River, Mass.	18	15	1	1	1	-	2	Jacksonville, Fla.	131	78	37	11	5	-	1	
Hartford, Conn.	U	U	U	U	U	U	U	Miami, Fla.	77	54	11	11	1	-	3	
Lowell, Mass.	26	20	5	1	-	-	4	Norfolk, Va.	50	27	14	3	2	4	-	
Lynn, Mass.	10	8	2	-	-	-	-	Richmond, Va.	44	25	13	1	3	2	-	
New Bedford, Mass.	28	21	5	1	1	-	4	Savannah, Ga.	49	36	9	2	-	2	1	
New Haven, Conn.	U	U	U	U	U	U	U	St. Petersburg, Fla.	48	31	12	3	1	1	2	
Providence, R.I.	48	38	8	2	-	-	3	Tampa, Fla.	133	80	38	9	4	2	7	
Somerville, Mass.	2	1	1	-	-	-	-	Washington, D.C.	98	41	39	5	1	12	2	
Springfield, Mass.	26	14	11	-	1	-	1	Wilmington, Del.	13	8	3	2	-	-	2	
Waterbury, Conn.	27	21	5	1	-	-	3	E.S. CENTRAL	722	458	165	45	27	26	46	
Worcester, Mass.	56	36	14	5	1	-	7	Birmingham, Ala.	148	92	38	7	5	5	13	
MID. ATLANTIC	2,003	1,408	402	124	43	25	101	Chattanooga, Tenn.	62	48	8	2	1	3	4	
Albany, N.Y.	45	32	8	3	2	-	5	Knoxville, Tenn.	83	55	19	5	1	3	-	
Allentown, Pa.	27	25	1	1	-	-	1	Lexington, Ky.	57	36	7	6	4	4	5	
Buffalo, N.Y.	95	70	17	6	-	2	5	Memphis, Tenn.	155	92	42	11	3	7	9	
Camden, N.J.	23	17	2	1	2	1	-	Mobile, Ala.	42	29	9	-	3	1	2	
Elizabeth, N.J.	11	7	4	-	-	-	1	Montgomery, Ala.	47	29	12	4	1	1	3	
Erie, Pa.	28	20	6	1	1	-	1	Nashville, Tenn.	128	77	30	10	9	2	10	
Jersey City, N.J.	41	26	10	1	3	1	-	W.S. CENTRAL	1,183	744	278	97	34	30	63	
New York City, N.Y.	1,021	734	195	61	19	11	41	Austin, Tex.	119	70	30	13	2	4	5	
Newark, N.J.	45	21	16	6	2	-	1	Baton Rouge, La.	24	18	4	2	-	-	-	
Paterson, N.J.	23	9	9	1	3	1	-	Corpus Christi, Tex.	43	31	5	3	1	3	2	
Philadelphia, Pa.	328	212	80	23	6	7	13	Dallas, Tex.	156	85	45	15	4	7	8	
Pittsburgh, Pa. [‡]	23	15	5	1	1	1	3	El Paso, Tex.	59	46	10	2	1	-	3	
Reading, Pa.	14	9	4	1	-	-	-	Ft. Worth, Tex.	94	59	19	8	3	5	3	
Rochester, N.Y.	119	91	19	7	2	-	17	Houston, Tex.	295	179	75	26	7	8	23	
Schenectady, N.Y.	21	16	3	2	-	-	1	Little Rock, Ark.	54	32	17	2	3	-	-	
Scranton, Pa.	26	23	3	-	-	-	1	New Orleans, La.	41	24	11	3	3	-	-	
Syracuse, N.Y.	56	41	9	4	1	1	4	San Antonio, Tex.	185	128	33	18	3	3	10	
Trenton, N.J.	18	9	6	3	-	-	1	Shreveport, La.	37	26	9	-	2	-	4	
Utica, N.Y.	22	18	2	2	-	-	5	Tulsa, Okla.	76	46	20	5	5	-	5	
Yonkers, N.Y.	17	13	3	-	1	-	1	MOUNTAIN	873	565	198	73	19	15	78	
E.N. CENTRAL	1,616	1,084	346	87	57	41	109	Albuquerque, N.M.	86	61	18	4	2	1	7	
Akron, Ohio	42	30	8	2	2	-	5	Boise, Idaho	27	15	6	4	2	-	4	
Canton, Ohio	33	26	7	-	-	-	3	Colo. Springs, Colo.	38	23	12	2	1	-	3	
Chicago, Ill.	269	143	76	24	16	9	14	Denver, Colo.	100	54	34	9	2	1	11	
Cincinnati, Ohio	58	44	9	1	3	1	4	Las Vegas, Nev.	300	196	63	27	6	6	26	
Cleveland, Ohio	179	129	36	11	3	-	6	Ogden, Utah	41	26	10	1	2	1	5	
Columbus, Ohio	169	112	37	7	5	8	13	Phoenix, Ariz.	78	52	20	5	1	-	7	
Dayton, Ohio	93	67	16	7	3	-	11	Pueblo, Colo.	26	19	4	3	-	-	4	
Detroit, Mich.	165	89	59	8	6	3	16	Salt Lake City, Utah	98	60	18	13	2	5	7	
Evansville, Ind.	31	24	5	1	-	1	1	Tucson, Ariz.	79	59	13	5	1	1	4	
Fort Wayne, Ind.	56	34	11	3	6	2	1	PACIFIC	1,186	831	213	93	25	24	97	
Gary, Ind.	7	5	2	-	-	-	-	Berkeley, Calif.	19	14	4	-	-	1	3	
Grand Rapids, Mich.	46	37	4	3	1	1	3	Fresno, Calif.	117	75	25	14	1	2	2	
Indianapolis, Ind.	168	105	39	9	5	10	8	Glendale, Calif.	17	11	6	-	-	-	4	
Lansing, Mich.	30	27	2	-	-	1	5	Honolulu, Hawaii	55	42	9	2	2	-	4	
Milwaukee, Wis.	75	55	12	1	4	3	7	Long Beach, Calif.	61	42	12	4	1	2	6	
Peoria, Ill.	39	32	4	2	-	1	4	Los Angeles, Calif.	324	231	55	22	9	7	34	
Rockford, Ill.	U	U	U	U	U	U	U	Pasadena, Calif.	U	U	U	U	U	U	U	
South Bend, Ind.	27	19	3	2	3	-	1	Portland, Oreg.	89	61	11	12	1	4	5	
Toledo, Ohio	83	67	10	5	-	1	3	Sacramento, Calif.	152	104	28	16	1	3	12	
Youngstown, Ohio	46	39	6	1	-	-	4	San Diego, Calif.	92	62	17	6	4	3	7	
W.N. CENTRAL	528	323	129	41	20	14	28	San Francisco, Calif.	U	U	U	U	U	U	U	
Des Moines, Iowa	69	43	19	3	2	2	1	San Jose, Calif.	U	U	U	U	U	U	U	
Duluth, Minn.	31	27	4	-	-	-	3	Santa Cruz, Calif.	33	25	7	1	-	-	3	
Kansas City, Kans.	20	12	7	-	1	-	2	Seattle, Wash.	96	65	16	10	4	1	7	
Kansas City, Mo.	65	42	15	4	1	3	1	Spokane, Wash.	50	41	8	1	-	-	6	
Lincoln, Neb.	24	18	5	1	-	-	2	Tacoma, Wash.	81	58	15	5	2	1	4	
Minneapolis, Minn.	48	30	13	3	1	1	4	TOTAL	9,577 [§]	6,320	2,090	682	263	215	591	
Omaha, Neb.	58	39	14	4	-	1	5									
St. Louis, Mo.	90	38	25	12	10	4	5									
St. Paul, Minn.	48	29	9	7	2	1	1									
Wichita, Kans.	75	45	18	7	3	2	4									

U: Unavailable. --: No reported cases.

* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ≥100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

† Pneumonia and influenza.

‡ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks.

§ Total includes unknown ages.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy each week, send an e-mail message to listserv@listserv.cdc.gov. The body content should read *SUBscribe mmwr-toc*. Electronic copy also is available from CDC's World-Wide Web server at <http://www.cdc.gov/mmwr> or from CDC's file transfer protocol server at <ftp://ftp.cdc.gov/pub/publications/mmwr>. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-96, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone 888-232-3228.


All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆U.S. Government Printing Office: 2004-633-140/00028 Region IV ISSN: 0149-2195




Time Sensitive Material

DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION
ATLANTA, GA 30333



6

ZIP 48106



OFFICIAL BUSINESS
PENALTY FOR PRIVATE USE \$300
RETURN SERVICE REQUESTED

0206 93036 T19569DS 0001
PROQUEST INFORMATION & LEARNING
PERIODICALS ACQUISITION
PO BOX 1346
ANN ARBOR MI 48106-1346

